Company intelligence / Profile preview

Xyngular

Ownership: Private
Employees: ~373
Development stage: Other

Overview

Xyngular markets science-backed dietary supplements for weight loss, digestive health, energy, and overall wellness. Products are manufactured in FDA registered/GMP facilities with third-party testing for quality. No clinical trial data typical of pharmaceutical development; efficacy claims based on ingredient studies and customer testimonials.

Therapeutic areas: RheumatologyPsychiatryGastroenterologyMetabolic Disorders
Modalities: Non-pharmacological therapy (dietary supplements)Protein (collagen supplement)Probiotic (Complete Probiotic)Small molecule (nutraceuticals and supplement ingredients)Peptides (collagen peptides in Complete Collagen)
Industry: Food & Nutrition

Beyond the preview

Go deeper on Xyngular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xyngular.

Explore the full profile